Protective effects of neurotrophic factor-secreting cells in a 6-OHDA rat model of parkinson disease

Stem Cells and Development

Volumn 18, Issue 8, 2009, Pages 1179-1190

  Sadan, Ofer ^a   Bahat Stromza, Merav ^b   Barhum, Yael ^a   Levy, Yossef S ^b   Pisnevsky, Anat ^b   Peretz, Hagit ^b   Ilan, Avihay Bar ^b   Bulvik, Shlomo ^c   Shemesh, Noam ^a   Krepel, Dana ^a   Cohen, Yoram ^a   Melamed, Eldad ^a   Offen, Daniel ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b Brainstorm Cell Therapeutics Ltd   (Israel)

^c LANIADO HOSPITAL   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; BRAIN DERIVED NEUROTROPHIC FACTOR; CYCLOSPORIN A; DOPAMINE; ENROFLOXACIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; IRON; OXIDOPAMINE; SOMATOMEDIN C;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BONE MARROW; CELL LABELING; CELL MIGRATION; CELL SURVIVAL; CELL TRANSPLANTATION; CIRCLING BEHAVIOR; CONTROLLED STUDY; CORPUS STRIATUM; CULTURE MEDIUM; DOPAMINERGIC SYSTEM; ENGRAFTMENT; GRAFT VERSUS HOST REACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MOTOR ACTIVITY; NERVE ENDING; NERVE REGENERATION; NEUROBLASTOMA CELL; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN FIELD TEST; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN SECRETION; PROTEIN SYNTHESIS; RAT; SECRETORY CELL;

ANIMALS; BEHAVIOR, ANIMAL; CELLS, CULTURED; DISEASE MODELS, ANIMAL; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MESENCHYMAL STEM CELLS; NERVE GROWTH FACTORS; OXIDOPAMINE; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; STEM CELL TRANSPLANTATION;

RATTUS;

EID: 67549118438     PISSN: 15473287     EISSN: None     Source Type: Journal    
DOI: 10.1089/scd.2008.0411     Document Type: Article

References (57)

1. Isacson O. (2003). The production and use of cells as therapeutic agents in neurodegenerative diseases. Lancet Neurol 2:417-424.
2. Pakkenberg B, A Moller, HJ Gundersen, A Mouritzen Dam and H Pakkenberg. (1991). The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method. J Neurol Neurosurg Psychiatry 54:30-33.
3. Murrell W, A Wetzig, M Donnellan, F Feron, T Burne, A Meedeniya, J Kesby, J Bianco, C Perry, P Silburn and A kay-Sim. (2008). Olfactory mucosa is a potential source for autologous stem cell therapy for Parkinson's disease. Stem Cells 26:2183-2192.
4. Geeta R, RL Ramnath, HS Rao and V Chandra. (2008). One year survival and signifi cant reversal of motor defi cits in parkinsonian rats transplanted with hESC derived dopaminergic neurons. Biochem Biophys Res Commun 373(2):258-264.
5. Hedlund E, J Pruszak, T Lardaro, W Ludwig, A Vinuela, KS Kim and O Isacson. (2008). Embryonic stem cell-derived Pitx3-enhanced green fl uorescent protein midbrain dopamine neurons survive enrichment by fl uorescence-activated cell sorting and function in an animal model of Parkinson's disease. Stem Cells 26:1526-1536.
6. Wernig M, JP Zhao, J Pruszak, E Hedlund, D Fu, F Soldner, V Broccoli, M Constantine-Paton, O Isacson and R Jaenisch. (2008). Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease. Proc Natl Acad Sci USA 105:5856-5861.
7. Barzilay R, T Ben-Zur, S Bulvik, E Melamed and D Offen. (2008). Lentiviral delivery of LMX1a enhances dopaminergic phenotype in differentiated human bone marrow mesenchymal stem cells. Stem Cells Dev 18:1-11.
8. Barzilay R, I Kan, T Ben-Zur, S Bulvik, E Melamed and D Offen. (2008). Induction of human mesenchymal stem cells into dopamine-producing cells with different differentiation protocols. Stem Cells Dev 17:547-554.
9. Bouchez G, L Sensebe, P Vourc'h, L Garreau, S Bodard, A Rico, D Guilloteau, P Charbord, JC Besnard and S Chalon. (2008). Partial recovery of dopaminergic pathway after graft of adult mesenchymal stem cells in a rat model of Parkinson's disease. Neurochem Int 52:1332-1342.
10. Laws, V Dhawan, AJ Stoessl, J Matcham, RJ Coffey and M Traub. (2006). Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 59:459-466.
11. Kan I, T Ben-Zur, Y Barhum, YS Levy, A Burstein, T Charlow, S Bulvik, E Melamed and D Offen. (2007). Dopaminergic differentiation of human mesenchymal stem cells-utilization of bioassay for tyrosine hydroxylase expression. Neurosci Lett 419:28-33.
12. Levy YS, D Merims, H Panet, Y Barhum, E Melamed and D Offen. (2003). Induction of neuron-specifi c enolase promoter and neuronal markers in differentiated mouse bone marrow stromal cells. J Mol Neurosci 21:121-132.
13. Levy YS, M Bahat-Stroomza, R Barzilay, A Burshtein, S Bulvik, Y Barhum, H Panet, E Melamed and D Offen. (2008). Regenerative effect of neural-induced human mesenchymal stromal cells in rat models of Parkinson's disease. Cytotherapy 10:340-352.
14. Trzaska KA, EV Kuzhikandathil and P Rameshwar. (2007). Specifi cation of a dopaminergic phenotype from adult human mesenchymal stem cells. Stem Cells 25:2797-2808.
15. Park HJ, PH Lee, OY Bang, G Lee and YH Ahn. (2008). Mesenchymal stem cells therapy exerts neuroprotection in a progressive animal model of Parkinson's disease. J Neurochem 107(1):141-151.
16. Muraoka K, T Shingo, T Yasuhara, M Kameda, WJ Yuen, T Uozumi, T Matsui, Y Miyoshi and I Date. (2008). Comparison of the therapeutic potential of adult and embryonic neural precursor cells in a rat model of Parkinson disease Laboratory investigation. J Neurosurg 108:149-159.
17. O'Keeffe FE, SA Scott, P Tyers, GW O'Keeffe, JW Dalley, R Zufferey and MA Caldwell. (2008). Induction of A9 dopaminergic neurons from neural stem cells improves motor function in an animal model of Parkinson's disease. Brain 131:630-641.
18. Freed CR, PE Greene, RE Breeze, WY Tsai, W DuMouchel, R Kao, S Dillon, H Winfi eld, S Culver, JQ Trojanowski, D Eidelberg and S Fahn. (2001). Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 344:710-719.
19. Olanow CW, CG Goetz, JH Kordower, AJ Stoessl, V Sossi, MF Brin, KM Shannon, GM Nauert, DP Perl, J Godbold and TB Freeman. (2003). A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 54:403-414.
20. Kordower JH, Y Chu, RA Hauser, TB Freeman and CW Olanow. (2008). Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med 14:504-506.
21. Li JY, E Englund, JL Holton, D Soulet, P Hagell, AJ Lees, T Lashley, NP Quinn, S Rehncrona, A Bjorklund, H Widner, T Revesz, O Lindvall and P Brundin. (2008). Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med 14:501-503.
22. Takahashi K, K Tanabe, M Ohnuki, M Narita, T Ichisaka, K Tomoda and S Yamanaka. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defi ned factors. Cell 131:861-872.
23. Peterson AL and JG Nutt. (2008). Treatment of Parkinson's disease with trophic factors. Neurotherapeutics 5:270-280.
24. Pascual A, M Hidalgo-Figueroa, JI Piruat, CO Pintado, R Gomez-Diaz and J Lopez-Barneo. (2008). Absolute requirement of GDNF for adult catecholaminergic neuron survival. Nat Neurosci 11:755-761.
25. Behrstock S, A Ebert, J McHugh, S Vosberg, J Moore, B Schneider, E Capowski, D Hei, J Kordower, P Aebischer and CN Svendsen. (2005). Human neural progenitors deliver glial cell line-derived neurotrophic factor to parkinsonian rodents and aged primates. Gene Ther 13:379-388.
26. Guan J, R Krishnamurthi, HJ Waldvogel, RLM Faull, R Clark and P Gluckman. (2000). N-terminal tripeptide of IGF-1 (GPE) prevents the loss of TH positive neurons after 6-OHDA induced nigral lesion in rats. Brain Res 859:286-292.
27. Lang AE, S Gill, NK Patel, A Lozano, JG Nutt, R Penn, DJ Brooks, G Hotton, E Moro, P Heywood, MA Brodsky, K Burchiel, P Kelly, A Dalvi, B Scott, M Stacy, D Turner, VG Wooten, WJ Elias, ER derived somatic cell therapy results in functional recovery and axonal plasticity following stroke in the rat. Exp Neurol 211:588-592.
28. Patel NK, M Bunnage, P Plaha, CN Svendsen, P Heywood and SS Gill. (2005). Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: A two-year outcome study. Ann Neurol 57:298-302.
29. Lindvall O and LU Wahlberg. (2008). Encapsulated cell biodelivery of GDNF: A novel clinical strategy for neuroprotection and neuroregeneration in Parkinson's disease? Exp Neurol 209:82-88.
30. Prockop DJ. (1997). Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 276:71-74.
31. Pittenger MF, AM Mackay, SC Beck, RK Jaiswal, R Douglas, JD Mosca, MA Moorman, DW Simonetti, S Craig and DR Marshak. (1999). Multilineage potential of adult human mesenchymal stem cells. Science 284:143-147.
32. Blondheim NR, YS Levy, T Ben-Zur, A Burshtein, T Cherlow, I Kan, R Barzilai, M Bahat-Stromza, Y Barhum, S Bulvik, E Melamed and D Offen. (2006). Human mesenchymal stem cells express neural genes, suggesting a neural predisposition. Stem Cells Dev 15:141-164.
33. Choong PF, PL Mok, SK Cheong, CF Leong and KY Then. (2007). Generating neuron-like cells from BM-derived mesenchymal stromal cells in vitro. Cytotherapy 9:170-183.
34. Kopen GC, DJ Prockop and DG Phinney. (1999). Marrow stromal cells migrate throughout forebrain and cerebellum, and they differentiate into astrocytes after injection into neonatal mouse brains. Proc Natl Acad Sci USA 96:10711-10716.
35. Mahay D, G Terenghi and SG Shawcross. (2008). Growth factors in mesenchymal stem cells following glial cell differentiation. Biotechnol Appl Biochem 51(Pt 4):167-176.
36. Kan I, E Melamed and D Offen. (2007). Autotransplantation of Bone Marrow-Derived Stem Cells as a Therapy for Neurodegenerative Diseases. (180):219-242.
37. Scolding N, D Marks and C Rice. (2008). Autologous mesenchymal bone marrow stem cells: practical considerations. J Neurol Sci 265:111-115.
38. Hellmann MA, H Panet, Y Barhum, E Melamed and D Offen. (2006). Increased survival and migration of engrafted mesenchymal bone marrow stem cells in 6-hydroxydopamine-lesioned rodents. Neurosci Lett 395:124-128.
39. Sadan O, N Shemesh, R Barzilay, M Bahat-Stromza, E Melamed, Y Cohen and D Offen. (2008). Migration of neurotrophic factorssecreting mesenchymal stem cells towards a quinolinic acid lesion as viewed by MRI. Stem Cells 26(10):2542-2551.
40. Wu X, J Hu, L Zhou, Y Mao, B Yang, L Gao, R Xie, F Xu, D Zhang, J Liu and J Zhu. (2008). In vivo tracking of superparamagnetic iron oxide nanoparticle-labeled mesenchymal stem cell tropism to malignant gliomas using magnetic resonance imaging Laboratory investigation. J Neurosurg 108:320-329.
41. Heyn C, CV Bowen, BK Rutt and PJ Foster. (2005). Detection threshold of single SPIO-labeled cells with FIESTA. Magn Reson Med 53:312-320.
42. Shapiro EM, K Sharer, S Skrtic and AP Koretsky. (2006). In vivo detection of single cells by MRI. Magn Reson Med 55:242-249.
43. Doucet C, I Ernou, Y Zhang, JR Llense, L Begot, X Holy and JJ Lataillade. (2005). Platelet lysates promote mesenchymal stem cell expansion: A safety substitute for animal serum in cellbased therapy applications. J Cell Physiol 205:228-236.
44. Paxinos G and C Watson. (1998). The rat brain, 4th ed. Academic Press, San Diego, CA.
45. Petroske E, GE Meredith, S Callen, S Totterdell and YS Lau. (2001). Mouse model of Parkinsonism: A comparison between subacute MPTP and chronic MPTP/probenecid treatment. Neuroscience 106:589-601.
46. Andrews EM, SY Tsai, SC Johnson, JR Farrer, JP Wagner, GC Kopen and GL Kartje. (2008). Human adult bone marrow.
47. Hardy SA, DJ Maltman and SA Przyborski. (2008). Mesenchymal stem cells as mediators of neural differentiation. Curr Stem Cell Res Ther 3:43-52.
48. Le Blanc K and O Ringden. (2007). Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med 262:509-525. (Pubitemid 47620502)
49. Evans JR and RA Barker. (2008). Neurotrophic factors as a therapeutic target for Parkinson's disease. Expert Opin Ther Targets 12:437-447.
50. Azizi SA, D Stokes, BJ Augelli, C DiGirolamo and DJ Prockop. (1998). Engraftment and migration of human bone marrow stromal cells implanted in the brains of albino rats-similarities to astrocyte grafts. Proc Natl Acad Sci USA 95:3908-3913.
51. Arnhold S, H Klein, FJ Klinz, Y Absenger, A Schmidt, Schinköthe T, K Brixius, J Kozlowski, B Desai, W Bloch and K Addicks. (2006). Human bone marrow stroma cells display certain neural characteristics and integrate in the subventricular compartment after injection into the liquor system. Eur J Cell Biol 85:551-565.
52. Kappes JC and X Wu. (2001). Safety considerations in vector development. Somat Cell Mol Genet 26:147-158.
53. Offen D, Y Sherki, E Melamed, M Fridkin, DE Brenneman and I Gozes. (2000). Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease. Brain Res 854:257-262.
54. Ouyang M and X Shen. (2006). Critical role of ASK1 in the 6-hydroxydopamine-induced apoptosis in human neuroblastoma SH-SY5Y cells. J Neurochem 97:234-244.
55. Schober A. (2004). Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res 318:215-224.
56. Steiner H and ST Kitai. (2001). Unilateral striatal dopamine depletion: time-dependent effects on cortical function and behavioural correlates. Eur J Neurosci 14:1390-1404.
57. Cho MS, YE Lee, JY Kim, S Chung, YH Cho, DS Kim, SM Kang, H Lee, MH Kim, JH Kim, JW Leem, SK Oh, YM Choi, DY Hwang, JW Chang and DW Kim. (2008). Highly effi cient and large-scale generation of functional dopamine neurons from human embryonic stem cells. Proc Natl Acad Sci USA 105:3392-3397.